Nuvilex (NASDAQ:PMCB) Trading Down 1% – Here’s Why

Shares of Nuvilex Inc. (NASDAQ:PMCB) dropped 1% during mid-day trading on Friday . The stock traded as low as $0.4855 and last traded at $0.4865. 45,370 shares traded hands during trading, a decline of 50% from the average daily volume of 91,511 shares. The stock had previously closed at $0.4913.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Nuvilex from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Nuvilex Trading Down 1.0%

The stock has a market cap of $5.23 million, a P/E ratio of -0.16 and a beta of 0.66. The firm’s 50-day simple moving average is $0.60 and its 200 day simple moving average is $0.69.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.